Compare Davita Inc (DVA) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs DexCom, Inc. — how do they compare? Davita Inc trades at $179.02 (market cap $11.38B), while DexCom, Inc. trades at $89.2 (market cap $33.79B). The key difference: DexCom, Inc. is far larger — about 3× Davita Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | DXCM | |
|---|---|---|
Market Cap | $11.38B | $33.79B |
Sector | Health | Health |
52-Week High | $240.96 | $89.53 |
52-Week Low | $103.87 | $54.84 |
Enterprise Value | $24.10B | $33.24B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
